Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
Bremelanotide (Vyleesi) causes nausea and temporary appetite suppression in roughly one-third of users. Learn the mechanism, clinical data from RECONNECT, and how to manage these effects during HSDD treatment.
Read clinical reviewA clinician-level review of bremelanotide (Vyleesi) safety and efficacy in patients with autoimmune conditions, including lupus, RA, MS, and Sjögren syndrome, with primary-literature citations.
Read clinical reviewA physician-reviewed analysis of bremelanotide (Vyleesi) and its effects on bone health and density, including melanocortin receptor biology, clinical trial data, and monitoring guidance for prescribers and patients.
Read clinical reviewA clinical-depth review of bremelanotide (Vyleesi) and cancer risk signals, covering FDA labeling, RECONNECT trial data, melanoma warnings, and practical prescribing guidance for premenopausal women with HSDD.
Read clinical reviewA physician-reviewed deep dive into bremelanotide (Vyleesi) cardiovascular effects, blood pressure changes, long-term safety data from RECONNECT, and clinical guidance for patients with cardiac risk factors.
Read clinical reviewA clinical deep-dive into bremelanotide (Vyleesi) and cognitive function. Learn what the RECONNECT trials found, what melanocortin receptors have to do with cognition, and what patients should expect.
Read clinical reviewAn evidence-based comparison of compounded bremelanotide and FDA-approved Vyleesi for HSDD, covering pharmacology, safety, efficacy data from RECONNECT, dosing, and how to choose between options.
Read clinical reviewA GRADE-level appraisal of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, including RECONNECT trial data, effect sizes, safety profile, and prescribing guidance.
Read clinical reviewA clinical deep-dive into bremelanotide (Vyleesi) hair and skin changes, including transient hyperpigmentation, flushing mechanisms, melanocortin pharmacology, and what the RECONNECT trial data actually show.
Read clinical reviewA clinician-level review of bremelanotide (Vyleesi) and liver function impact, covering hepatotoxicity data from RECONNECT, ALT/AST monitoring thresholds, and FDA labeling requirements for premenopausal women with HSDD.
Read clinical reviewA clinician-reviewed breakdown of bremelanotide's (Vyleesi) effects on mood, anxiety, depression, and emotional well-being, drawn from the RECONNECT trials and post-market safety data.
Read clinical reviewA physician-reviewed deep dive into how bremelanotide (Vyleesi) affects metabolism, thermogenesis, and energy expenditure, with primary-literature citations and clinical guidance for prescribers and patients.
Read clinical reviewA clinician-level review of bremelanotide (Vyleesi) microdosing protocols, standard FDA-approved dosing, RECONNECT trial data, and what off-label dose reduction means in practice for premenopausal women with HSDD.
Read clinical reviewA physician-reviewed guide to muscle preservation strategies for women using Vyleesi (bremelanotide) for HSDD, including dosing, nausea management, nutrition timing, and resistance training protocols backed by primary literature.
Read clinical reviewWhy bremelanotide (Vyleesi) stops working or never works, and what clinicians and patients can do about it. Evidence-based troubleshooting from the RECONNECT trials with dosing, timing, and combination strategies.
Read clinical reviewA comprehensive clinical review of bremelanotide (Vyleesi) use after bariatric surgery, covering pharmacokinetics, dosing, drug interactions, and HSDD management in post-bariatric premenopausal women.
Read clinical reviewA clinician-level guide to the bremelanotide (Vyleesi) pre-surgery hold window, covering FDA labeling, cardiovascular pharmacology, anesthesia interactions, and practical perioperative management protocols.
Read clinical reviewA comprehensive, physician-reviewed guide to bremelanotide (Vyleesi) rebound effects after stopping, covering pharmacology, RECONNECT trial data, discontinuation patterns, and what patients and clinicians should expect.
Read clinical reviewA physician-reviewed deep dive into bremelanotide (Vyleesi) and renal function: pharmacokinetics, clinical trial safety data, FDA labeling guidance, and practical prescribing advice for patients with kidney concerns.
Read clinical reviewEvidence-based guidance on safely restarting bremelanotide (Vyleesi) after acute illness, including dose timing, contraindications, and pharmacology from the RECONNECT trial and FDA prescribing information.
Read clinical reviewA clinician-level review of how seasonal factors, temperature, light exposure, and mood changes affect bremelanotide (Vyleesi) efficacy and tolerability in premenopausal women with HSDD.
Read clinical reviewA clinician-level review of how bremelanotide (Vyleesi) affects sexual desire, arousal, and distress in premenopausal women with HSDD, based on RECONNECT trial data and FDA-approved prescribing information.
Read clinical reviewA clinician-level review of how bremelanotide (Vyleesi) affects sleep architecture, including melanocortin receptor pharmacology, clinical trial data from RECONNECT, and practical dosing guidance for women with HSDD.
Read clinical reviewMD-level guidance on using bremelanotide (Vyleesi) across time zones, in hot or cold climates, and during travel disruptions. Covers storage, dosing windows, nausea management, and the RECONNECT trial data clinicians and patients need.
Read clinical reviewA physician-reviewed, week-by-week guide to bremelanotide (Vyleesi) covering what to expect in the first month: dosing, side effects, efficacy timelines, and clinical trial data.
Read clinical review